Indivior Pharmaceuticals, Inc.
Financials
Valuation Metrics
Indivior Pharmaceuticals, Inc.'s Market Cap is $4.12B. At end of 2025 it was $4.49B. Ranked #1482 of 3,121 in US market (top 47%), #515 of 1,463 on NASDAQ (top 35%), #88 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.12B | US#1,482/3,121 Sec#88/266 |
| Revenue | $1.33B | US#1,711/3,121 Sec#44/266 |
| Net Income | $355M | US#1,018/3,121 Sec#34/266 |
| Total Assets | $1.23B | US#2,381/3,121 Sec#83/266 |
| Net Assets | $-208M | US#2,992/3,121 Sec#260/266 |
| Employees | 827 | US#2,072/3,121 Sec#61/266 |
| Value | ||
| P/E | 11.61x | US#507/3,121 Sec#12/266 |
| PEG | 0.07x | US#161/3,121 Sec#10/266 |
| P/S | 3.10x | US#1,774/3,121 Sec#50/266 |
| EV/EBITDA | 10.21x | US#882/3,121 Sec#28/266 |
| FCF Yield | -2.69% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | 28.79% | US#38/3,121 Sec#8/266 |
| Op. Margin | 38.89% | US#304/3,121 Sec#15/266 |
| Revenue Growth | 13.46% | US#1,009/3,121 Sec#86/266 |
| Earnings Growth | 177.34% | US#174/3,121 Sec#11/266 |
| Financial Health | ||
| Total Debt | $509M | US#1,867/3,121 Sec#63/266 |
| FCF | $-111M | US#2,650/3,121 Sec#152/266 |
| Cash | $222M | US#1,652/3,121 Sec#100/266 |
| Current Ratio | 0.84x | US#2,467/3,121 Sec#264/266 |
| Net Debt/EBITDA | 0.66x | US#839/3,121 Sec#44/266 |
| Performance | ||
| 1Y Return | 52.38% | US#510/3,121 Sec#100/266 |
| 1M Return | -10.66% | US#2,385/3,121 Sec#180/266 |
| From 52W High | -18.52% | US#1,253/3,121 Sec#85/266 |
| 1Y MDD | -21.37% | US#810/3,121 Sec#35/266 |
| Trading | ||
| Volume | 4,139,100 shares | US#1,202/3,121 Sec#122/266 |
| Trading Value | $145M | US#1,337/3,121 Sec#103/266 |
| Per Share | ||
| EPS | $3.00 | US#1,057/3,121 Sec#30/266 |
| BPS | $-1.76 | US—/3,121 Sec—/266 |
Company Info
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.